The inhibitor of apoptosis protein fusion c-IAP2•MALT1 stimulates NF-κB activation independently of TRAF1 AND TRAF2

The inhibitors of apoptosis (IAPs) are a family of cell death inhibitors found in viruses and metazoans. All members of the IAP family have at least one baculovirus IAP repeat (BIR) motif that is essential for their anti-apoptotic activity. The t(11, 18)(q21;q21) translocation fuses the BIR domains of c-IAP2 with the paracaspase/MALT1 (mucosa-associated lymphoid tissue) protein, a critical mediator of T cell receptor-stimulated activation of NF-kappa B. The c-IAP2 center dot MALT1 fusion protein constitutively activates the NF-kappa B pathway, and this is considered critical to malignant B cell transformation and lymphoma progression. The BIR domains of c-IAP1 and c-IAP2 interact with tumor necrosis factor receptor-associated factors 1 and 2 (TRAF1 and TRAF2). Here we investigated the importance of TRAF1 and TRAF2 for c-IAP2(.)MALT1-stimulated NF-kappa B activation. We identified a novel epitope within the BIR1 domains of c-IAP1 and c-IAP2 that is crucial for their physical interaction with TRAF1 and TRAF2. The c-IAP2(.)MALT1 fusion protein associates with TRAF1 and TRAF2 using the same binding site. We explored the functional relevance of this interaction and established that binding to TRAF1 and TRAF2 is not required for c-IAP2(.)MALT1-stimulated NF-kappa B activation. Furthermore, gene ablation of TRAF2 or combined down-regulation of TRAF1 and TRAF2 did not affect c-IAP2(.)MALT1 stimulated signaling. However, TRAF1/2-binding mutants of c-IAP2(.)MALT1 still oligomerize and activate NF-kappa B, suggesting that oligomerization might be important for signaling of the fusion protein. Therefore, the t(11, 18)(q21; q21) translocation creating the c-IAP2(.)MALT1 fusion protein activates NF-kappa B and contributes to human malignancy in the absence of signaling adaptors that might otherwise regulate its activity.